[HTML][HTML] The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
A Grinshpun, SM Tolaney, HJ Burstein… - NPJ Breast …, 2023 - nature.com
The combination of an endocrine agent with a CDK4/6 inhibitor is the standard of care in the
first-line setting for patients with hormone receptor-positive, HER2-negative metastatic …
first-line setting for patients with hormone receptor-positive, HER2-negative metastatic …
The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
A Grinshpun, S Tolaney, H Burstein… - NPJ Breast …, 2023 - europepmc.org
The combination of an endocrine agent with a CDK4/6 inhibitor is the standard of care in the
first-line setting for patients with hormone receptor-positive, HER2-negative metastatic …
first-line setting for patients with hormone receptor-positive, HER2-negative metastatic …
[HTML][HTML] The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
A Grinshpun, SM Tolaney, HJ Burstein… - NPJ Breast …, 2023 - ncbi.nlm.nih.gov
The combination of an endocrine agent with a CDK4/6 inhibitor is the standard of care in the
first-line setting for patients with hormone receptor-positive, HER2-negative metastatic …
first-line setting for patients with hormone receptor-positive, HER2-negative metastatic …
The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
A Grinshpun, SM Tolaney, HJ Burstein… - NPJ Breast …, 2023 - search.proquest.com
The combination of an endocrine agent with a CDK4/6 inhibitor is the standard of care in the
first-line setting for patients with hormone receptor-positive, HER2-negative metastatic …
first-line setting for patients with hormone receptor-positive, HER2-negative metastatic …
The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer.
A Grinshpun, SM Tolaney, HJ Burstein… - NPJ Breast …, 2023 - search.ebscohost.com
The combination of an endocrine agent with a CDK4/6 inhibitor is the standard of care in the
first-line setting for patients with hormone receptor-positive, HER2-negative metastatic …
first-line setting for patients with hormone receptor-positive, HER2-negative metastatic …
The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
A Grinshpun, SM Tolaney, HJ Burstein… - NPJ breast …, 2023 - pubmed.ncbi.nlm.nih.gov
The combination of an endocrine agent with a CDK4/6 inhibitor is the standard of care in the
first-line setting for patients with hormone receptor-positive, HER2-negative metastatic …
first-line setting for patients with hormone receptor-positive, HER2-negative metastatic …
[引用][C] The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer.
A Grinshpun, SM Tolaney, HJ Burstein… - NPJ Breast …, 2023 - europepmc.org
The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative
metastatic breast cancer. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …
metastatic breast cancer. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …